HPS has 11 subtypes; 100% of patients with type 1, 2, or 4 will develop pulmonary fibrosis, usually by their mid-30s.

In his book, Dr. Flora explains how artificial intelligence can finally match cancer's relentless ability to evolve and adapt.

Rare Cancer Day takes place annually on September 23.

Experts believe treatments for AATD-related liver disease will be available in 5 to 10 years.

Dr. Ku, an oncologist, hosts the podcast, “Val-You Based Care,” that emphasizes empathy and building trust in health care.

Hereditary alpha-tryptasemia and SM exhibit overlapping biochemical and clinical features that may present challenges for accurate diagnosis.

Emerging research supports a potential association between primary biliary cholangitis (PBC) and kidney disease.

MCL therapy is shifting toward targeted and immune-based approaches, making the order of treatment increasingly consequential.

Immunosenescence offers a novel framework for IPF pathogenesis and treatment, though associated biomarkers and therapies await clinical validation.

Growing evidence suggests viral infections can exacerbate myasthenia gravis (MG) or even contribute to its development.